Kadcyla, known as an "antibody-drug conjugate, " represents "a completely new way" to treat HER2 positive metastatic breast cancer, said Dr. Hal Barron, chief medical officer and head of global product development for Genentech.
CNN: New late-stage breast cancer treatment approved